RATNAVEER (RATNAVEER)

Research Summary — What the data shows

• Business: Stainless-steel products manufacturer with integrated scrap reprocessing, 31-country export reach, and a CCL diversification project (₹472 Cr approved capex, ~60% complete, Nov 2026 target commissioning).
• Financials: FY26 revenue ₹1,069 Cr (+19.8% YoY), PAT ₹64 Cr (+36.2%). Q1 FY27: revenue ₹315 Cr (+18.9%), PAT ₹18 Cr (+20%). OPM stable ~10%.
• Technical picture: Stage 2. RSI 74.2. Supertrend(10,3) BULLISH at ₹304.75. Price is extended vs long-term averages — orderly consolidation would improve reward-to-risk.
• Valuation context: Illustrative P/E scenarios at 12×/18×/22× FY28E EPS suggest a wide range depending on CCL execution. See Estimates section.
• Key dependency: CCL commissioning and ramp-up is the primary catalyst; delay materially changes the financial trajectory.

Research Framework

• Business quality: Profitable, growing, integrated, investment-grade rated (IVR A−/Stable, Infomerics 2026). Customer concentration (top-10 ≈ 72%) and negative FCF during capex cycle are offset concerns.
• Technical context: Stage 2 with RSI 74.2 — momentum is strong but the stock is extended vs moving averages. Review the Technicals section for full Weinstein and CAN SLIM analysis.
• Key variables to monitor: CCL commissioning milestone, rights-issue subscription outcome, CFO turning positive, and whether SMA50 holds on any pullback.
• Risk frame: Leverage (₹335 Cr net debt), rights-issue dilution, and import dependency for CCL raw materials. Full risk register in the Risks section.

Score Interpretation

EFS 71.8 combines earnings quality (75.0), sales growth (86.7), financial strength (55.0), and institutional backing (61.0).

Investment Score 94.5 blends EFS with the current technical score 92.4 — the tape is stronger than the balance-sheet evidence, meaning the stock can screen well for momentum without removing execution, leverage, or valuation risk.

What they do

Manufactures and sells stainless-steel products (tubes, pipes, sheets, washers, fittings) with five integrated facilities in Gujarat. In-house scrap reprocessing and R&D; 2,500+ washer SKUs. ISO 9001/14001/45001 certified.

Top-10 customers ≈ 72% of FY25 revenue — concentration risk to monitor.

Scale & reach

FY26: 46,668 MT processed · 219 clients · 89 distribution partners · 31-country export footprint (Europe, North America, Asia Pacific, Middle East).

Market cap ₹2,558 Cr · P/E 37.8x · ROCE 12.3% · ROE 12.4% · Book ₹83.8

CCL expansion

Copper Clad Laminate project — electronics-grade material for PCBs. Total approved capex ₹472.34 Cr (Gujarat Electronics Policy). ~60% complete; commercial production targeted Nov 2026.

Dependency: high import content for raw materials; customer qualification and ramp-up timelines are management guidance, not contracted revenue.

Key drivers

• Revenue beat: ₹315 Cr (+18.9% YoY) driven by volume expansion and export mix improvement across SS tubes, pipes, and sheets.
• OPM flat at 10%: CCL pre-operational overhead absorbed; structural margin re-rating awaits CCL commissioning and volume ramp.
• PAT beat (+20% YoY): Operating leverage and lower finance costs post QIP-driven debt reduction.
• QoQ recovery strong: Revenue +26.5% and PAT +5.9% vs Q4 FY26 — seasonal Q4 dip normalised.

What to test in next quarter

• Does OPM expand above 11% as CCL overhead reduces pre-commissioning?
• Is revenue acceleration above ₹315 Cr run-rate sustainable, or seasonal?
• Rights-issue subscription outcome and use-of-proceeds disclosure.
• CCL machinery installation milestone — is Nov 2026 still on track?
• CFO and FCF turning positive after capex cycle peaks?

Project specs

• Product: Copper Clad Laminate (CCL) — electronics-grade base material for PCBs
• Approved capex: ₹472.34 Cr (Gujarat Electronics Policy in-principle approval)
• ECMS-approved scope: ₹338 Cr — reconcile these two figures before forecasting returns
• Location: Gujarat (integrated with existing SS facilities)
• Target commissioning: November 2026
• Technical support: 18–24 months post-commissioning from equipment supplier

Milestones to track

• ~60% project complete as of Q1 FY27 management disclosure (Jul 2026)
• Machinery installation confirmation (next quarterly filing)
• Customer qualification / first commercial dispatch
• Utilisation ramp (0 → steady-state over 12–18 months post-commissioning)
• Return on capital vs. stated project IRR
• Monitoring-agency report on deployment of rights-issue proceeds

Risks

• Commissioning delay → FY28E estimates need revision
• Customer qualification slower than expected (new product category)
• Two different approved capex figures (₹338 Cr vs ₹472 Cr) — total capital commitment unclear until reconciled in a filing
• Rights-issue proceeds may be insufficient if capex runs over

Chairman's highlights

• Engineering Value. Shaping Tomorrow
• lasting value is created through engineering excellence
• expanded product portfolio
• strengthened manufacturing ecosystem
• entered new markets
• built enduring partnerships across continents.

Stan Weinstein Stage Analysis

Classified as Stage 2: price ₹304.75 is above key moving averages (SMA20, SMA50, SMA200). This is the trend phase where a prior base has resolved upward and institutional demand may be becoming visible.

Trend quality: RSI 74.2 is at/above conventional overbought levels. The stock is ~3% below its 52-week high — momentum is strong but immediate reward-to-risk is less attractive after the sharp run.

Supertrend(10,3): BULLISH (ST line ₹251.70, EOD 2026-09-04). Computed from full 500+ bar history in market.equity_eod — not a short rolling window. Use full price history; short windows produce unreliable ATR bands.

William O'Neil / CAN SLIM Lens

• C — Current earnings: Q1 FY27 PAT ₹18 Cr, revenue ₹315 Cr. Confirm next two quarters sustain growth.
• A — Annual earnings: FY24–FY26 PAT ₹31 Cr → ₹64 Cr; OPM stable ~10%. Quality of growth matters more than headline revenue.
• N — New: CCL project is the new-product catalyst — execution milestone, not delivered earnings.
• S — Supply/demand: Monitor volume on advances and declines, rights-issue dilution, and whether new supply absorbs demand.
• L — Leader: Useful only if relative strength persists vs. benchmark.
• I/M: Institutional ownership low (FII 3.5%, DII 2%); bulk-deal buy-side activity a positive signal but not sustained institutional accumulation yet.

Practical conclusion: strong watchlist candidate; demand a defined pullback or a clean, volume-backed retest before treating the setup as actionable.

▲ Optimistic scenario

22× FY28E EPS ₹21.8 = implied value ~₹480. Conditions required: CCL commissions on time (Nov 2026), ramps to 60% utilisation by FY28, margin expands to 13%, revenue ~₹1,800 Cr.

Illustrative P/E math — not a price target.

→ Base scenario

18× FY28E EPS ₹21 = implied value ~₹380. Conditions: CCL commissions Q1 FY28 (one-quarter delay), 40% utilisation, OPM 11–12%, revenue ~₹1,550 Cr.

18× = mid-cap SS manufacturer peer median. Not a price target.

▼ Adverse scenario

12× FY28E EPS ₹18.5 = implied value ~₹220. Conditions: CCL delayed 12+ months, rights-issue undersubscribed, leverage rises, OPM stuck at 10%, revenue ~₹1,300 Cr.

Illustrative downside math — not a price target.

▲ Factors improving since last review

• Revenue re-acceleration above ₹249–286 Cr band (Q1 FY27 ₹315 Cr)
• Credit rating upgraded to IVR A−/Stable (Infomerics 2026)
• QIP-strengthened balance sheet; reserves ₹601 Cr vs ₹318 Cr pre-QIP
• PAT +20% YoY despite QIP dilution headwind

→ Unchanged factors

• OPM structural band 10–11% — no demonstrated expansion yet
• Export footprint maintained (31 countries, diverse geographies)
• Top-10 customer concentration ~72% — ongoing monitoring item
• Weinstein Stage 2 technical picture intact

⚠ Key risks requiring monitoring

• CCL execution: Nov 2026 target — machinery installation milestone unconfirmed
• EPS dilution from QIP share-count expansion (equity ₹53 Cr → ₹68 Cr)
• Rights-issue dilution and subscription outcome (record date 26 Aug 2026)
• Negative CFO/FCF during capex cycle — watch for inflection
• Capex scope discrepancy (₹338 Cr ECMS vs ₹472 Cr Gujarat approval — reconcile)